Science
Science|Prilenia and Ferrer
Prilenia and Ferrer Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease
October 22, 2026 · 4:34 AMPrilenia Therapeutics B.V. and Ferreri today announced that the confirmatory Phase 3 PRECISE-HD study of investigational pridopidine in Huntington's disease (HD) has received authorization to begin in participating EU Me…
Science|Ferrer and Prilenia
Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease
Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease....
October 22, 2026 · 3:00 AM
Science|IQM Quantum Computers
IQM Quantum Computers Announces Conference Call to Report Third Quarter 2026 Financial Results on November 5, 2026
IQM Quantum Computers will host a conference call and live webcast on Thursday, November 5, 2026 to discuss its third-quarter 2026 financial results....
October 22, 2026 · 2:00 AMScience|Arcus Biosciences
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatment of cancer and immune diseases, today announced the p…
October 21, 2026 · 10:53 PM
Science|QIAGEN and EQT Private Equity
QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) (“QIAGEN” or the “Company”) and the EQT XI fund (“EQT Private Equity”) today announced an agreement under which Crown NL Bidco B.V. (the “Bidder”) announced its dec…
October 21, 2026 · 5:43 PMScience|Arcus Biosciences
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today announ…
October 21, 2026 · 4:22 PM
Science|Medpace Holdings, Inc.
Medpace Holdings, Inc. Reports Third Quarter 2026 Results
Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Results Revenue for the three months ended September 30, 20…
October 21, 2026 · 4:15 PM
Science|CooperSurgical
CooperSurgical Announces the Donation of More Than 300 Cord Blood Samples and Additional Funding to Support Ongoing Stem Cell Research at the University of Toronto
CooperSurgical announces the donation of more than 300 cord blood samples and additional funding to support ongoing stem cell research...
October 21, 2026 · 4:10 PM
Science|UL Solutions
UL Solutions Expands Capabilities to Help Companies Navigate Growing Packaging and Sustainability Regulations
UL Solutions Inc., a global leader in applied safety science, today announced the expansion of its extended producer responsibility (EPR) capabilities to help companies manage an increasingly complex and rapidly evolving…
October 21, 2026 · 4:10 PM
Science|Acadia Pharmaceuticals to
Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2026 financial results on Wednesday, November 4, 2026, after the close of the U.S. financial markets. Acadia’s management team…
October 21, 2026 · 4:05 PMLatest from leading organizations
Explore recent announcements by organization
